375 related articles for article (PubMed ID: 16494628)
1. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting.
Gold J; Batterham MJ; Rekers H; Harms MK; Geurts TB; Helmyr PM; Silva de Mendonça J; Falleiros Carvalho LH; Panos G; Pinchera A; Aiuti F; Lee C; Horban A; Gatell J; Phanuphak P; Prasithsirikul W; Gazzard B; Bloch M; Danner SA;
HIV Med; 2006 Apr; 7(3):146-55. PubMed ID: 16494628
[TBL] [Abstract][Full Text] [Related]
2. Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
Mulligan K; Zackin R; Clark RA; Alston-Smith B; Liu T; Sattler FR; Delvers TB; Currier JS; ;
Arch Intern Med; 2005 Mar; 165(5):578-85. PubMed ID: 15767536
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of nandrolone decanoate in wasting associated with HIV.
Saha B; Rajadhyaksha GC; Ray SK
J Indian Med Assoc; 2009 May; 107(5):295-9. PubMed ID: 19886384
[TBL] [Abstract][Full Text] [Related]
4. The use of testosterone in the AIDS wasting syndrome.
Corcoran C; Grinspoon S
AIDS Clin Care; 1999 Apr; 11(4):25-6, 33-4. PubMed ID: 11366208
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of nandrolone and testosterone in adult male HIV patients with AIDS wasting syndrome (AWS): a randomized, double-blind, placebo-controlled trial.
Sardar P; Jha A; Roy D; Majumdar U; Guha P; Roy S; Banerjee R; Banerjee AK; Bandyopadhyay D
HIV Clin Trials; 2010; 11(4):220-9. PubMed ID: 20974577
[TBL] [Abstract][Full Text] [Related]
6. Anabolic steroids in COPD: a review and preliminary results of a randomized trial.
Sharma S; Arneja A; McLean L; Duerksen D; Leslie W; Sciberras D; Lertzman M
Chron Respir Dis; 2008; 5(3):169-76. PubMed ID: 18684793
[TBL] [Abstract][Full Text] [Related]
7. Body composition and anthropometry in bodybuilders: regional changes due to nandrolone decanoate administration.
Hartgens F; Van Marken Lichtenbelt WD; Ebbing S; Vollaard N; Rietjens G; Kuipers H
Int J Sports Med; 2001 Apr; 22(3):235-41. PubMed ID: 11354529
[TBL] [Abstract][Full Text] [Related]
8. Effects of testosterone and nandrolone on cardiac function: a randomized, placebo-controlled study.
Chung T; Kelleher S; Liu PY; Conway AJ; Kritharides L; Handelsman DJ
Clin Endocrinol (Oxf); 2007 Feb; 66(2):235-45. PubMed ID: 17223994
[TBL] [Abstract][Full Text] [Related]
9. Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy.
Van Loan MD; Strawford A; Jacob M; Hellerstein M
AIDS; 1999 Feb; 13(2):241-8. PubMed ID: 10202830
[TBL] [Abstract][Full Text] [Related]
10. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss.
Strawford A; Barbieri T; Neese R; Van Loan M; Christiansen M; Hoh R; Sathyan G; Skowronski R; King J; Hellerstein M
J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Feb; 20(2):137-46. PubMed ID: 10048900
[TBL] [Abstract][Full Text] [Related]
11. Clinical trials update in human immunodeficiency virus wasting.
Muurahainen N; Mulligan K
Semin Oncol; 1998 Apr; 25(2 Suppl 6):104-11. PubMed ID: 9625392
[TBL] [Abstract][Full Text] [Related]
12. A randomized, placebo-controlled trial of nandrolone decanoate in human immunodeficiency virus-infected men with mild to moderate weight loss with recombinant human growth hormone as active reference treatment.
Storer TW; Woodhouse LJ; Sattler F; Singh AB; Schroeder ET; Beck K; Padero M; Mac P; Yarasheski KE; Geurts P; Willemsen A; Harms MK; Bhasin S
J Clin Endocrinol Metab; 2005 Aug; 90(8):4474-82. PubMed ID: 15914526
[TBL] [Abstract][Full Text] [Related]
13. [Anabolic therapy in patients with HIV infections].
Gruzdev BM; Ivannikov EV; Gorbacheva ES
Ter Arkh; 1999; 71(11):35-7. PubMed ID: 10626332
[TBL] [Abstract][Full Text] [Related]
14. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men.
Lovejoy JC; Bray GA; Greeson CS; Klemperer M; Morris J; Partington C; Tulley R
Int J Obes Relat Metab Disord; 1995 Sep; 19(9):614-24. PubMed ID: 8574271
[TBL] [Abstract][Full Text] [Related]
15. Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men.
Cuerda C; Zugasti A; Bretón I; Camblor M; Miralles P; García P
Nutr Clin Pract; 2005 Feb; 20(1):93-7. PubMed ID: 16207650
[TBL] [Abstract][Full Text] [Related]
16. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss.
Batterham MJ; Garsia R
Int J Androl; 2001 Aug; 24(4):232-40. PubMed ID: 11454075
[TBL] [Abstract][Full Text] [Related]
17. L-ornithine alpha-ketoglutarate in HIV infection: effects on muscle, gastrointestinal, and immune functions.
Karsegard VL; Raguso CA; Genton L; Hirschel B; Pichard C
Nutrition; 2004 Jun; 20(6):515-20. PubMed ID: 15165613
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of nandrolone decanoate for treatment of wasting in patients with HIV infection.
Gold J; High HA; Li Y; Michelmore H; Bodsworth NJ; Finlayson R; Furner VL; Allen BJ; Oliver CJ
AIDS; 1996 Jun; 10(7):745-52. PubMed ID: 8805865
[TBL] [Abstract][Full Text] [Related]
19. Nutritional effect of nandrolone decanoate in predialysis patients with chronic kidney disease.
Eiam-Ong S; Buranaosot S; Eiam-Ong S; Wathanavaha A; Pansin P
J Ren Nutr; 2007 May; 17(3):173-8. PubMed ID: 17462549
[TBL] [Abstract][Full Text] [Related]
20. Single-agent/combination therapy of human immunodeficiency virus-related wasting.
Wanke C
Semin Oncol; 1998 Apr; 25(2 Suppl 6):98-103. PubMed ID: 9625391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
